Core Insights - The company reported a record revenue of €858 million for Q1 2025, reflecting a 7.0% increase compared to Q1 2024, with organic revenue growth at 5.5% [2][8] - Digital revenue growth was particularly strong at 17.0%, with programmatic digital out-of-home (OOH) media revenue increasing by 29.9% [3][4] - The company anticipates low single-digit organic revenue growth for Q2 2025 due to global economic uncertainties and the impact of major events like the Paris Olympic Games and UEFA Euro 2024 [5][16] Revenue Breakdown - Total revenue for Q1 2025 was €858 million, up from €801.6 million in Q1 2024, with organic growth of 5.5% after excluding foreign exchange impacts [8][10] - Revenue by segment: - Street Furniture: €422.5 million, +5.4% reported growth, +5.3% organic growth [10][12] - Transport: €315 million, +9.3% reported growth, +6.1% organic growth [10][13] - Billboard: €120.5 million, +7.1% reported growth, +4.6% organic growth [10][14] Geographic Performance - All geographic regions experienced growth in Q1 2025, with notable contributions from Rest of Europe, North America, and the Rest of the World [4][9] - The Asia-Pacific region showed low single-digit growth, primarily due to flat performance in China [13] Future Outlook - For Q2 2025, the company expects organic revenue growth to be low single-digit, with Street Furniture pacing mid-single digit while Transport and Billboard are currently flat [5][16] - The company will hold its Annual General Meeting of Shareholders on May 14, 2025, and will report half-year results on July 31, 2025 [16]

Bioventus (BVS) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Dave Crawford - VP - IR & TreasurerRobert Claypoole - CEOMark Singleton - Senior VP & CFOMichaela Smith - Equity Research Associate Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareRobert Marcus - Analyst Operator Day and welcome to the BioVentis First Quarter twenty twenty five Conference Call. All participants will be in a listen only mode. Please note this event is being record ...

Brilliant Earth Group (BRLT) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Colin Bourland - Vice President - Strategy, Business Development, & Investor RelationsBeth Gerstein - CEO & DirectorJeffrey Kuo - CFOOliver Chen - Managing Director - Retail, Luxury, New Platforms Sector HeadDana Telsey - CEO and Chief Research Officer Conference Call Participants Ashley Owens - Vice President & Senior Equity Research AnalystDylan Carden - Research Analyst Operator Good day and thank you for sta ...

Core Viewpoint - Johnson & Johnson (JNJ) and AbbVie (ABBV) are both major U.S. pharmaceutical companies with strong pipelines and global operations, but they face different challenges and growth prospects as they approach 2025, which is expected to be a catalyst year for both companies [2]. Group 1: Johnson & Johnson (JNJ) - JNJ's diversified business model, operating through over 275 subsidiaries, provides resilience against economic cycles [3]. - The Innovative Medicine unit showed a 4.4% organic sales growth in Q1 2025 despite the loss of exclusivity for Stelara, with growth expected to be driven by key products and new drug launches [4][5]. - JNJ's MedTech business is experiencing challenges, particularly in China, due to the volume-based procurement program and competitive pressures [6]. - The loss of U.S. patent exclusivity for Stelara in 2025 led to a 33.7% decline in its sales in Q1 2025, with generics expected to further impact sales and profits [7]. - JNJ is facing over 62,000 lawsuits related to its talc-based products, which has created a negative sentiment around the stock [8][9]. - JNJ's 2025 sales and EPS estimates indicate a year-over-year increase of 2.7% and 6.2%, respectively, with the EPS estimate slightly rising over the past month [14]. - JNJ's stock has risen 8.1% year-to-date, outperforming the industry average of 2.4% [21]. - JNJ's current price/earnings ratio is 14.44, slightly below the industry average of 15.70, and its dividend yield is 3.2% [23][24]. - JNJ expects operational sales growth to accelerate in the second half of 2025, driven by new product launches [29]. Group 2: AbbVie (ABBV) - AbbVie has successfully managed the loss of exclusivity for Humira, launching new immunology drugs Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined sales by 2027 [10]. - The oncology strategy is gaining traction with contributions from newer products, and AbbVie has several early/mid-stage pipeline candidates with blockbuster potential [11]. - AbbVie has been active in acquisitions, strengthening its pipeline in immunology and entering the obesity market through a licensing deal [12]. - AbbVie faces near-term challenges, including biosimilar erosion of Humira and competitive pressures on its cancer drug Imbruvica [13]. - AbbVie's 2025 sales and EPS estimates imply a year-over-year increase of 6.4% and 21.2%, respectively, with the EPS estimate slightly declining over the past month [17]. - AbbVie's stock has risen 12.4% year-to-date, also outperforming the industry average [21]. - AbbVie's current price/earnings ratio is 15.22, lower than the industry average but higher than its 5-year mean of 12.23, with a dividend yield of around 3.4% [23][24]. - AbbVie expects to achieve mid-single-digit revenue growth in 2025 and a high single-digit CAGR through 2029, with no significant loss of exclusivity events anticipated for the rest of the decade [31].

Bioventus (BVS) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Day and welcome to the BioVentis First Quarter twenty twenty five Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Mr. Dave Crawford. Please go ahead, sir. Speaker1 Thanks, Chuck, and good morning, everybody, and thanks for joining us. It's my pleasure to welcome you to the BioVentis twenty twenty five first quarter earnings confere ...

Financial Data and Key Metrics Changes - Consolidated revenue increased by 14.3% or $17.1 million to $136.8 million, driven by strong performance in Genie Retail Energy [10] - Consolidated gross profit rose by 10.6% to $37.4 million, while gross margin decreased by 90 basis points to 27.3% [11][12] - Consolidated net income attributable to stockholders increased by $10.6 million or $0.40 per share from $8.1 million or $0.30 per share a year earlier [13] Business Line Data and Key Metrics Changes - Genie Retail Energy (GRE) revenue jumped 17.8% to $132.5 million, primarily due to investments made to grow the customer base [10] - Electricity revenue climbed 16.4% to $104.1 million, contributing 78.6% of GRE's revenues, with kilowatt hours sold increasing by 23.5% [10] - Revenue from natural gas sales increased by 26.8% to $28.4 million, reflecting increases in both terms sold and revenues per term sold [11] Market Data and Key Metrics Changes - Customer churn in the first quarter was 5.5%, unchanged from the year-ago quarter, indicating effective customer retention efforts [5] - The company ended the quarter with approximately 413,000 meters served, comprising 402,000 Residential Customer Equivalents (RCEs) [4] Company Strategy and Development Direction - The company is expanding its customer base and has begun marketing in California, with plans to offer gas in Kentucky in the second quarter [5] - The community solar project in Lansing, New York, is on track for completion in the third quarter and is expected to be EBITDA accretive immediately upon going online [6] Management's Comments on Operating Environment and Future Outlook - Management highlighted strong operational and financial results, indicating a return to normalized results for the retail energy business [3] - The company confirmed its full-year adjusted EBITDA guidance of $40 million to $50 million, suggesting confidence in future performance [14] Other Important Information - The company returned $3.9 million to stockholders through dividends and share repurchases during the first quarter [7] - Cash, cash equivalents, and marketable securities totaled $210.2 million as of March 31, 2025, an increase of $9.2 million in the quarter [13] Q&A Session Summary - There were no questions during the Q&A session, leading to the conclusion of the conference call [16]

Core Viewpoint - Bioventus Inc. reported a decline in revenue for the first quarter of 2025, primarily due to the divestiture of its Advanced Rehabilitation Business, but achieved organic revenue growth across all business segments, indicating resilience in its strategic execution despite macroeconomic challenges [2][6]. Financial Performance - Worldwide revenue for Q1 2025 was $123.9 million, a decrease of 4.3% from $129.5 million in the same period last year, largely impacted by the divestiture [2][5]. - Organic revenue increased by 5.0%, reflecting positive growth across all three business segments [2][6]. - The net loss attributable to Bioventus Inc. was $2.6 million, an improvement from a net loss of $4.9 million in the prior-year period [3][4]. - Adjusted EBITDA for the quarter was $19.2 million, down from $22.6 million in the previous year, primarily due to the divestiture and planned growth investments [3][6]. Revenue Breakdown by Business - U.S. revenue from Pain Treatments was $52.7 million, up 4.0% year-over-year, while Surgical Solutions revenue increased by 6.5% to $40.8 million [5][8]. - Restorative Therapies revenue fell by 32.9% to $17.0 million, significantly affected by the divestiture of the Advanced Rehabilitation Business [5][9]. - International revenue totaled $13.4 million, a decline of 12.0%, with Pain Treatments and Surgical Solutions showing modest growth, while Restorative Therapies revenue dropped by 47.1% [5][9]. Strategic Developments - The company reiterated its financial guidance for 2025, expecting net sales between $560 million and $570 million, reflecting organic growth of approximately 6.1% to 8.0% when accounting for the divestiture [10][13]. - Adjusted EBITDA guidance for 2025 is set between $112 million and $116 million, indicating a potential increase in Adjusted EBITDA margin compared to 2024 [10][13]. - Non-GAAP EPS is projected to be between $0.64 and $0.68, representing a growth of 30.6% to 38.8% [10][13].

Core Viewpoint - ALK reported strong Q1 results with a 12% organic revenue growth and a 50% increase in operating profit, driven by robust sales across all regions and product lines [1][7][9] Financial Performance - Total revenue for Q1 2025 reached DKK 1,522 million, up from DKK 1,351 million, reflecting a 12% growth in local currencies and a 13% increase in reported terms [3][7] - Operating profit (EBIT) surged by 50% to DKK 469 million, compared to DKK 316 million in Q1 2024, with an EBIT margin of 31%, up from 23% [3][7] - Free cash flow nearly tripled to DKK 330 million, driven by increased earnings, while CAPEX remained stable at DKK 57 million [7] Sales Growth - Global tablet sales increased by 22% to DKK 857 million, with European tablet sales growing by 17% due to an influx of new patients [7][8] - Revenue growth in Europe and International markets was 10% and 24% respectively, while North America saw a 14% rebound [7] Strategic Developments - The launch of the house dust mite tablet for children positively impacted sales, with initial market responses exceeding expectations [8] - ALK is progressing well with the market access for the neffy adrenaline nasal spray, expecting first launches in Europe by Q3 2025 [8] - The company has entered a four-year agreement with ARS Pharma to co-promote the neffy adrenaline nasal spray in the USA [8] Outlook - The full-year revenue growth outlook remains unchanged at 9-13%, primarily driven by higher volumes in allergy immunotherapy and anaphylaxis products [6][9] - The EBIT margin is anticipated to improve by 5 percentage points to around 25%, supported by revenue growth and optimization efforts [9]

一季度我国规模以上互联网企业完成互联网业务收入4118亿元，同比增长1.4%。研发经费增速加快， 一季度规模以上互联网企业共投入研发经费204.5亿元，同比增长4.6%，增速较1—2月份提高1.8个百分 点。东部地区互联网业务收入稳步增长，一季度东部地区完成互联网业务收入3676亿元，同比增长 2.9%，高于全国增速1.5个百分点，占全国互联网业务收入的89.3%。京津冀地区互联网业务收入较快增 长，一季度京津冀地区完成互联网业务收入1251亿元，同比增长7.1%，占全国互联网业务收入的 30.4%。(工信微报) ...

Fabrinet (FN) Q3 2025 Earnings Call May 05, 2025 05:00 PM ET Company Participants Garo Toomajanian - VP - IR & Corporate DevelopmentSeamus Grady - CEOCsaba Sverha - CFOKarl Ackerman - Managing Director - Equity ResearchSamik Chatterjee - Executive DirectorSteven Fox - Founder & CEOGeorge Wang - Vice President Conference Call Participants Mike Genovese - Senior Research AnalystRyan Koontz - Senior AnalystTim Savageaux - MD & Senior Research Analyst Operator Good afternoon. Welcome to Fabrinet's Financial Res ...